Table 5:  Primary and secondary outcomes based on HBP* and CBP** at end-point in 284 non-obese patients with type 2 diabetes mellitus.

Outcomes

Patient status: HBP* at end-point  in 284 non-obese patients

Patient status: CBP** at end-point in 284 non-obese patients

 

Hypertension (n = 78)

Normotension (n = 206)

Hazard ratio (95% CI)

P

Hypertension (n = 133)

Normotension (n = 151)

Hazard ratio (95% CI)

P

Primary outcome

Death

22

33

2.4 (1.6-5.8)

0.0008

28

27

1.2 (0.7-2.1)

0.5803

Secondary outcome

Microvascular complications

80

22

1.8 (1.2-2.0)

0.0455

50

52

1.1 (0.8-1.7)

0.3156

Macrovascular complications

16

26

0.8 (1.6-6.9)

0.3763

38

4

4.8 (1.6-5.6)

0.0009

 

 

 

 

 

 

 

 

 

 

 

 

Characteristics of non-obese patients on HBP and CBP measured at end-point are shown in table 1. The non-obesity was defined by the criteria of Japan Society for the Study of Obesity. Body mass Index (BMI) with < 25.0 kg/m2 was defined as non-obesity. The 400 patients in each group were classified as having non-obesity and hypertension or normotension according to values of blood pressure as same threshold of normotension with less than 130 mm Hg of systolic blood pressure measured in the home (HBP*) and in the clinic (CBP**) at end-point, respectively. Differences in primary and secondary outcomes for events between non-obese patients with hypertension or normotension measured at end-point in each group were assessed using survival curves from the Kaplan-Meier method, and comparisons were analyzed using hazard ratio by the log-rank test. CI, confidence interval. Two-tailed values of P < 0.05 were defined as statistically significant.